Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients

Table 2 Tumor response according to VS Classification

	Chemotherapy VS-G(%)	VS-P(%)	P^a	Chemotherapy+Bev VS-G(%)	VS-P(%)	P^a
PR	9 (31.0)	0 (0.0)	0.304	19 (61.3)	3 (50.0)	0.670
SD	17 (58.6)	5 (83.3)	0.377	11 (35.5)	3 (50.0)	0.653
PD	2 (6.9)	1 (16.7)	0.442	1 (3.2)	0 (0.0)	1.000
PR+SD	26 (89.7)	5 (83.3)	0.546	30 (96.8)	6 (100.0)	1.000

PR partial response, SD stable disease, PD progression disease, Bev bevacizumab
^aTumor response was compared using X² test in two groups

ISSN: 1475-2867